路透8月5日 - 礼来公司 LLY.N 周三上调了全年营收预期,寄望于其重磅GLP-1减肥药和糖尿病药物的需求持续走强。
此举发生在竞争对手诺和诺德公司 NOVOb.CO 上调 (link) 全年利润和销售额预测不到一天之后,诺和诺德寄望于其口服药物Wegovy,以期在利润丰厚的肥胖症市场上夺回被礼来公司抢占的市场份额。
礼来公司目前预计营收将在850亿至870亿美元之间,而此前预测为820亿至850亿美元。
路透8月5日 - 礼来公司 LLY.N 周三上调了全年营收预期,寄望于其重磅GLP-1减肥药和糖尿病药物的需求持续走强。
此举发生在竞争对手诺和诺德公司 NOVOb.CO 上调 (link) 全年利润和销售额预测不到一天之后,诺和诺德寄望于其口服药物Wegovy,以期在利润丰厚的肥胖症市场上夺回被礼来公司抢占的市场份额。
礼来公司目前预计营收将在850亿至870亿美元之间,而此前预测为820亿至850亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.